Fig. 4.

The effects of EA and the DRD1 agonist SKF38393 on pain-related allodynia and anxiety-like behaviors induced by SNI in mice. A Schematic of EA treatment and drug injection and behavioral testing. B Diagram showing the cannulation location (left) and a representative coronal section of the BLA from a mouse brain showing injection of the cannula tip (right). C The effect of treatment in each group on the PWTs. (n = 9–10 per group). D–F The effect of treatment in each group on anxiety-like behaviors in the EPM (D) and OFT (E–F). (n = 8–10 per group). G Representative diagram showing tracked movement and activity heatmaps from the EPM. H Representative diagram showing tracked movement and activity heatmaps from the OFT. Data are expressed as the mean ± SEM. Tukey’s post hoc test: ⁺p < 0.05 compared with the sham + vehicle group; ^#p < 0.05 compared with the SNI + vehicle group; ^$p < 0.05 compared with the SNI + SKF38393 group; *p < 0.05 comparison of two groups